- Home
- KTTA vs CYBR Comparison
KTTA vs CYBR Comparison
Compare KTTA & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KTTA | CYBR |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 24.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KTTA | CYBR |
|---|---|---|
| Price | $1.15 | $450.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 30 |
| Target Price | $3.00 | ★ $458.48 |
| AVG Volume (30 Days) | ★ 21.7M | 616.0K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,302,851,000.00 |
| Revenue This Year | N/A | $36.30 |
| Revenue Next Year | N/A | $18.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 43.26 |
| 52 Week Low | $0.28 | $288.63 |
| 52 Week High | $3.85 | $526.19 |
Technical Indicators
Market Signals| Indicator | KTTA | CYBR |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 41.40 |
| Support Level | $1.10 | $442.65 |
| Resistance Level | $1.22 | $467.03 |
| Average True Range (ATR) | 0.12 | 9.61 |
| MACD | -0.01 | -0.32 |
| Stochastic Oscillator | 32.54 | 23.13 |
Price Performance
Historical ComparisonAbout KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.